ObsEva Announces Sale of Ebopiprant Agreement to XOMA for up to $113 Million
22 Nov 2022 //
GLOBENEWSWIRE
XOMA Acquires Royalty and Milestone License to Ebopiprant
22 Nov 2022 //
GLOBENEWSWIRE
ObsEva to Present Ebopiprant Data at Society for Reproductive Investigation
02 Jul 2021 //
GLOBENEWSWIRE